Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Subcutaneous sumatriptan eases cilostazol-induced headache in patients with migraine

Key clinical point: Subcutaneous sumatriptan significantly reduces cilostazol-induced headache in patients with migraine without aura compared with placebo.

Major finding: Sumatriptan injection significantly reduced headache score from 0 to 2 hours (P = .0003). The difference in median headache scores was significant at 2 hours (P = .01) and 4 hours (P = .0007) after sumatriptan treatment.

Study details: In a randomized, double-blind, crossover design, 30 participants received 200 mg cilostazol orally and cilostazol-induced headache was treated with subcutaneous sumatriptan.

Disclosures: The study was funded by Candys Foundation and Lundbeck Foundation. The authors declared no conflicts of interest.


Falkenberg K et al. Cephalalgia. 2020 Mar 26. doi: 10.1177/0333102420915166.